Lack of Data to Support ICI Retreatment in Advanced Melanoma
Source: Cancer Therapy Advisor, April 2023
Immune checkpoint inhibitor (ICI) retreatment in advanced melanoma is used in clinical practice, but there is a lack of evidence to support it, according to research presented at the NCCN 2023 Annual Conference.
“Although immune checkpoint inhibitors and targeted therapies revolutionized the treatment of advanced melanoma over the past few decades, the majority of patients experience disease progression after initial treatment, and options are limited in this setting. Checkpoint inhibitor retreatment is common, despite a lack of comparative evidence to support its use,” said study presenter Daniel Olson, MD, of the University of Chicago Comprehensive Cancer Center in Illinois.
To evaluate the current evidence supporting the use of ICI retreatment in the setting of advanced melanoma, Dr Olson and colleagues conducted a systematic review of the literature. The review included 8 studies — 6 retrospective analyses, 1 single-arm phase 2 trial, and 1 exploratory subgroup analysis.